Fisetin supplementation could ameliorate hyperlipidemia and insulin resistance through regulating the IRS1Tyr608/AKT/GSK3β/FoxO1 signaling pathway, the expression of phosphorylated IRS1Tyr608, AKT, FoxO1 and GSK3β was markedly decreased by the intervention of fisetin in the kidneys of HFD-fed mice (Ge et al., 2019). Here, GSK3B is linked to hyperlipidemia.